Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Gsk plc (GSK)

1K + Investors. Track Smart Money conviction in GSK. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +48
Streak
5Q ▲
Buyers last Q
49%

Smart Money Signals — GSK

Based on 1037 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 5 quarters in a row

last 6Q
For 5 consecutive quarters, more hedge funds added GSK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
1,037 hedge funds hold GSK right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +23% more funds vs a year ago

fund count last 6Q
+195 new funds entered over the past year (+23% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟠

More sellers than buyers — 49% buying

472 buying486 selling
Last quarter: 486 funds reduced or exited vs 472 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-34 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 113 → 108 → 183 → 149. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

65% of holders stayed for 2+ years

■ 65% conviction (2yr+) ■ 16% medium ■ 20% new
671 out of 1,037 hedge funds have held GSK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
🚀

Acceleration phase — new buyers rushing in

95 → 113 → 108 → 183 → 149 new funds/Q
New funds entering each quarter: 113 → 108 → 183 → 149. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 70% veterans vs 22% newcomers

■ 70% veterans ■ 9% 1-2yr ■ 22% new
Entry-cohort mix of 1,060 holders: 739 (70%) are 2+ year veterans, 93 entered 1–2 years ago, and 228 (22%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 77% AUM from top-100 funds

77% from top-100 AUM funds
49 of 1029 holders are among the 100 largest funds by AUM, controlling 77% of total institutional value in GSK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — GSK

In 2026 Q1, 472 hedge funds were net buyers of GSK (149 opened a new position, 323 added to an existing one), while 486 reduced or exited (385 trimmed, 101 sold completely) — a 49% buyer ratio, indicating roughly balanced activity. This marks 5 consecutive quarters of net institutional buying — a persistent conviction signal. 77% of total institutional value in GSK is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +48 funds (more new holders than closures). Total institutional holders: 1037.

Hedge Fund Ownership: GSK

How many hedge funds hold GSK — quarterly history vs. share price
Quarterly hedge fund ownership of GSK vs. share price

Market Analysis: GSK

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: GSK

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Gsk plc (GSK) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much GSK has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 74d ago
GSK
-3.9%
XLV
+4.9%

GSK outperformed XLV by -8.8% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 29d ago
GSK
+6.8%
XLV
+6.0%

Since the filing became public, GSK outperformed XLV by +0.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

35 top-rated funds 6 high-conviction
Consensus
6.8
/ 10
breadth
×
Elite
3.9
/ 10
conviction
Hedge Fund Positioning: GSK
1K + Investors

Track Smart Money conviction in GSK. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 1026 989 3.74%
13F Shares 378M 403M -6.12%
Total Value $19.15B $18.79B 1.93%
New Positions 144 183 -39
Increased Positions 317 306 +11
Closed Positions 107 74 +33
Reduced Positions 376 337 +39
Total Calls 15 14 7.14%
Total Puts 14 9 55.56%
PUT/CALL Ratio 0.93 0.64 Neutral

Statistics: GSK

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

1K + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GSK. Verified SEC 13F-HR filings.

QUARTER:
Top 25 GSK holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Eversept Partners, LP 5.20% 1,785,175 $98.5M
2 Callodine Capital Management, LP 4.86% 1,259,477 $69.5M
3 Mondrian Investment Partners LTD 4.12% 4,987,393 $275.3M
4 Abc Arbitrage SA 3.97% 541,753 $29.9M
5 Hillman Capital Management, Inc. 3.73% 97,432 $5.4M
6 Equity Investment Corp 3.48% 3,221,035 $177.8M
7 Sio Capital Management, LLC 3.05% 385,879 $21.3M
8 Nia Impact Advisors, LLC 2.98% 121,637 $6.7M
9 Clean Yield Group 2.52% 161,978 $8.9M
10 Miller Howard Investments Inc /Ny 2.46% 1,629,351 $89.9M
11 Keating Investment Counselors Inc 2.39% 175,168 $9.7M
12 Altrius Capital Management Inc 2.12% 193,180 $10.7M
13 Walled Lake Planning & Wealth Management, LLC 1.93% 118,898 $6.6M
14 Twin City Private Wealth, LLC 1.88% 44,445 $2.5M
15 Brentview Investment Management LLC 1.87% 78,510 $4.3M
16 Dodge & Cox 1.78% 58,662,974 $3.24B
17 Christine Messmer Pc 1.75% 49,718 $2.7M
18 Arjuna Capital 1.73% 123,202 $6.8M
19 Robinson Value Management, Ltd. 1.66% 53,990 $3.0M
20 Hourglass Capital, LLC 1.66% 144,213 $8.0M
21 Stockman Wealth Management, Inc. 1.65% 270,147 $14.9M
22 Kahn Brothers Group Inc 1.58% 160,982 $8.9M
23 Letko, Brosseau & Associates Inc 1.46% 1,644,613 $90.8M
24 Advisory Research Inc 1.39% 204,282 $11.3M
25 Parrish Capital LLC 1.34% 30,227 $1.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Gsk plc (GSK)

What does the Smart Money Trend signal show for GSK?

Buying streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds added GSK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GSK?

More sellers than buyers — 49% buying: Last quarter: 486 funds reduced or exited vs 472 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for GSK holders?

Elite ownership — 77% AUM from top-100 funds: 49 of 1029 holders are among the 100 largest funds by AUM, controlling 77% of total institutional value in GSK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held GSK?

65% of holders stayed for 2+ years: 671 out of 1,037 hedge funds have held GSK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Gsk plc (GSK) following the 2026 Q1 hedge fund 13F filings?

As of today, GSK has moved +6.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of +0.8%. Since the quarter end (March 31, 2026), GSK has gained -3.9% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →